Do analysts rate CCM or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Concord Medical Services 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CCM or BRTX?

Concord Medical Services has higher revenue and earnings than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Concord Medical Services $460.51M 0.04 -$13.27M N/A N/A Biorestorative Therapies $357.87K 28.48 -$14.24M -$1.07 N/A

Do analysts rate BRTX or MRAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Marpai 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer BRTX or BMGL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Basel Medical Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BRTX or BMGL?

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biorestorative Therapies $357.87K 28.48 -$14.24M -$1.07 N/A Basel Medical Group $8.90M 1.46 -$9.50M N/A N/A

Do analysts prefer ADVB or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Advanced Biomed 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BRTX or ACON?

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 142.72%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Biorestorative Therapies (BRTX) Competitors

$0.40 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.40 0.00 (-0.75%)

As of 07/2/2026 07:25 PM Eastern

Compare

BRTX vs. CCM, MRAI, BMGL, ADVB, and ACON

Should you buy Biorestorative Therapies stock or one of its competitors? MarketBeat compares Biorestorative Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biorestorative Therapies include Concord Medical Services (CCM), Marpai (MRAI), Basel Medical Group (BMGL), Advanced Biomed (ADVB), and Aclarion (ACON). These companies are all part of the "healthcare" industry.

How does Biorestorative Therapies compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Concord Medical Services has a beta of -0.97, suggesting that its stock price is 197% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Concord Medical Services has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Concord Medical Services' return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Concord Medical Services has higher revenue and earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$460.51M	0.04	-$13.27M	N/A	N/A
Biorestorative Therapies	$357.87K	28.48	-$14.24M	-$1.07	N/A

In the previous week, Concord Medical Services had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 1 mentions for Concord Medical Services and 0 mentions for Biorestorative Therapies. Concord Medical Services' average media sentiment score of 0.00 equaled Biorestorative Therapies'average media sentiment score.

Company	Overall Sentiment
Concord Medical Services	Neutral
Biorestorative Therapies	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.4% of Biorestorative Therapies shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Concord Medical Services beats Biorestorative Therapies on 7 of the 10 factors compared between the two stocks.

How does Biorestorative Therapies compare to Marpai?

Biorestorative Therapies (NASDAQ:BRTX) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Biorestorative Therapies' average media sentiment score of 0.00 equaled Marpai'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Marpai	Neutral

Biorestorative Therapies has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$357.87K	28.48	-$14.24M	-$1.07	N/A
Marpai	$34.87M	0.54	-$28.75M	-$0.87	N/A

Marpai has a net margin of -85.70% compared to Biorestorative Therapies' net margin of -3,088.27%. Marpai's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Marpai	-85.70%	N/A	-100.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Biorestorative Therapies has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Marpai has a beta of 4.92, meaning that its share price is 392% more volatile than the broader market.

69.4% of Biorestorative Therapies shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Comparatively, 46.1% of Marpai shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Marpai beats Biorestorative Therapies on 8 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Basel Medical Group?

Biorestorative Therapies (NASDAQ:BRTX) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Basel Medical Group had 4 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Basel Medical Group and 0 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 0.00 equaled Basel Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Basel Medical Group	Neutral

Biorestorative Therapies has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Basel Medical Group has higher revenue and earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$357.87K	28.48	-$14.24M	-$1.07	N/A
Basel Medical Group	$8.90M	1.46	-$9.50M	N/A	N/A

69.4% of Biorestorative Therapies shares are held by institutional investors. 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Basel Medical Group has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Basel Medical Group's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Basel Medical Group	N/A	N/A	N/A

Summary

Basel Medical Group beats Biorestorative Therapies on 6 of the 10 factors compared between the two stocks.

How does Biorestorative Therapies compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Advanced Biomed has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

In the previous week, Advanced Biomed had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for Advanced Biomed and 0 mentions for Biorestorative Therapies. Advanced Biomed's average media sentiment score of 0.83 beat Biorestorative Therapies' score of 0.00 indicating that Advanced Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Advanced Biomed	Positive
Biorestorative Therapies	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

69.4% of Biorestorative Therapies shares are held by institutional investors. 27.0% of Advanced Biomed shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Advanced Biomed has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Advanced Biomed's return on equity of 87.74% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	87.74%	64.49%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Advanced Biomed has higher earnings, but lower revenue than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$4.82	1.04
Biorestorative Therapies	$357.87K	28.48	-$14.24M	-$1.07	N/A

Summary

Advanced Biomed beats Biorestorative Therapies on 9 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Aclarion?

Biorestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biorestorative Therapies has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Aclarion has lower revenue, but higher earnings than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$357.87K	28.48	-$14.24M	-$1.07	N/A
Aclarion	$80K	95.02	-$7.23M	-$9.03	N/A

Biorestorative Therapies has a net margin of -3,088.27% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -54.41% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
Aclarion	-10,320.51%	-54.41%	-51.71%

In the previous week, Biorestorative Therapies' average media sentiment score of 0.00 equaled Aclarion'saverage media sentiment score.

Company	Overall Sentiment
Biorestorative Therapies	Neutral
Aclarion	Neutral

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 142.72%. Given Aclarion's stronger consensus rating and higher possible upside, analysts clearly believe Aclarion is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aclarion beats Biorestorative Therapies on 9 of the 14 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRTX vs. The Competition

Export

Metric	Biorestorative Therapies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.19M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.37	21.61	28.02	24.70
Price / Sales	28.48	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	10.00	8.66	10.96	6.46
Net Income	-$14.24M	$23.81M	$3.57B	$337.01M
7 Day Performance	5.26%	3.39%	2.12%	1.69%
1 Month Performance	-1.23%	10.81%	5.25%	3.81%
1 Year Performance	-74.75%	62.61%	33.29%	23.90%

Biorestorative Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRTX Biorestorative Therapies	0.6947 of 5 stars	$0.40 flat	N/A	-74.7%	$10.19M	$357.87K	N/A	7
CCM Concord Medical Services	0.311 of 5 stars	$4.54 -3.8%	N/A	-26.2%	$20.49M	$65.85M	N/A	970	News Coverage Gap Up High Trading Volume
MRAI Marpai	N/A	$0.74 -6.7%	N/A	-48.0%	$19.74M	$34.87M	N/A	150	Gap Up
BMGL Basel Medical Group	0.1648 of 5 stars	$7.09 +2.0%	N/A	-59.5%	$10.88M	$8.90M	N/A	36	Earnings Report Analyst Downgrade Gap Down
ADVB Advanced Biomed	0.9911 of 5 stars	$4.84 +4.1%	N/A	N/A	$7.68M	N/A	0.93	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biorestorative Therapies (BRTX) Competitors

BRTX vs. CCM, MRAI, BMGL, ADVB, and ACON

How does Biorestorative Therapies compare to Concord Medical Services?

Summary

How does Biorestorative Therapies compare to Marpai?

Summary

How does Biorestorative Therapies compare to Basel Medical Group?

Summary

How does Biorestorative Therapies compare to Advanced Biomed?

Summary

How does Biorestorative Therapies compare to Aclarion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biorestorative Therapies (BRTX) Competitors

BRTX vs. CCM, MRAI, BMGL, ADVB, and ACON

How does Biorestorative Therapies compare to Concord Medical Services?

Which has more volatility and risk, CCM or BRTX?

Is CCM or BRTX more profitable?

Which has stronger earnings and valuation, CCM or BRTX?

Does the media refer more to CCM or BRTX?

Do analysts rate CCM or BRTX?

Do insiders and institutionals have more ownership in CCM or BRTX?

Summary

How does Biorestorative Therapies compare to Marpai?

Does the media refer more to BRTX or MRAI?

Which has higher valuation and earnings, BRTX or MRAI?

Is BRTX or MRAI more profitable?

Do analysts rate BRTX or MRAI?

Which has more risk and volatility, BRTX or MRAI?

Do insiders and institutionals hold more shares of BRTX or MRAI?

Summary

How does Biorestorative Therapies compare to Basel Medical Group?

Does the media refer more to BRTX or BMGL?

Which has more volatility & risk, BRTX or BMGL?

Do analysts prefer BRTX or BMGL?

Which has better earnings & valuation, BRTX or BMGL?

Do insiders and institutionals hold more shares of BRTX or BMGL?

Is BRTX or BMGL more profitable?

Summary

How does Biorestorative Therapies compare to Advanced Biomed?

Which has more risk & volatility, ADVB or BRTX?

Does the media favor ADVB or BRTX?

Do analysts prefer ADVB or BRTX?

Do insiders and institutionals have more ownership in ADVB or BRTX?

Is ADVB or BRTX more profitable?

Which has better earnings and valuation, ADVB or BRTX?

Summary

How does Biorestorative Therapies compare to Aclarion?

Do insiders & institutionals have more ownership in BRTX or ACON?

Which has more volatility & risk, BRTX or ACON?

Which has better earnings and valuation, BRTX or ACON?

Is BRTX or ACON more profitable?

Does the media prefer BRTX or ACON?

Do analysts rate BRTX or ACON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools